Details of the Drug

General Information of Drug (ID: DMUKBI2)

Drug Name
mRNA-2752
Synonyms mRNA-OX40L/IL-23/IL-36 gamma
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
mRNA therapy
Cross-matching ID
TTD ID
DC5A9Q

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Replacement [2]
Interleukin-36 gamma (IL36G) TT8SLDN IL36G_HUMAN Replacement [2]
TAX transcriptionally-activated glycoprotein 1 (OX40) TTBW580 TNFL4_HUMAN Replacement [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03739931) Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants With Advanced Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Moderna Therapeutics.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
8 Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
9 Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.
10 Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
11 Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
12 J Clin Oncol 33, 2015 (suppl; abstr 3056).
13 Clinical pipeline report, company report or official report of Moderna Therapeutics.